In most cases ecthyma gangrenosum is a consequence of Pseudomonas aeruginosa bloodstream infection in immunodeficient patients. This bacterium is characterized by multi-drug resistance and has a number of mechanisms that allow it to survive even in extreme conditions. The disease is...

Introduction Haemangioma, one of the most common benign neoplasms of early childhood, is a significant clinical problem due to cosmetic reasons but also because of possible health complications. Aim Presentation of the method and results of treatment of infantile haemangiomas (IHs) using...

Coronavirus Disease 2019 (COVID-19) pandemic caused an increase in the demand for personal protective equipment (PPE) and disruptions in production chains, resulting in an acute shortage of PPE. A possible solution to this problem was additive manufacturing (AM) technology - allowing for a quick start of the production of PPE and potentially able to meet the demand until the production is restored. In addition, AM allows for the production of PPE prototypes with potentially greater comfort of use or degree of protection. In order to assess the production of PPE in AM during the COVID-19 pandemic, previously published articles in this field were analyzed. After analyzing abstracts and full texts, 30 original works were selected from the initially collected 487 articles. Based on the analyzed literature, it was found that there are not enough studies comparing traditional and AM PPE as well as not enough comparisons of the different types of AM PPE with each other. In many cases, researchers focused only on the subjective assessment of the comfort of using PPE, without assessing their effectiveness in preventing infections. Despite that, AM has a great potential to quickly produce lacking PPE. Respirators and shields made by AM were rated by the vast majority of users as comfortable to wear. Some of the respirators could be adapted to a specific user, by designing on the basis of a face scan or after warming up the finished print and modeling the shape.

The genus Lyssavirus spp. currently includes 14 species that are responsible for causing rabies, rabies-like and rabies-related diseases. The first symptoms of infection are similar to a cold and mainly include fever, headache and general fatigue. Then comes brain dysfunction and acute neurological symptoms, and ultimately – in most cases – death. Lyssaviruses are spread mainly through direct contact with the carrier that contains the viral reservoir. The gold standard in diagnostics is the method of direct immunofluorescence, through which viral antigens are detected – mainly in the saliva of a patient. Currently, rabies treatment is an experimental form of therapy according to the Milwaukee protocol. 1. Introduction. 2. Systematics. 2.1. Lagos bat virus. 2.2. Mokola virus. 2.3 Duvenhage virus. 2.4. European bat 1 lyssavirus. 2.5. European bat 2 lyssavirus. 2.6. Australian bat lyssavirus. 3. Characteristics. 3.1. Molecular structure. 3.2. Genome and gene expression. 3.3. Life cycle. 4. Pathogenicity. 4.1. Pathogenesis. 4.2. Rabies symptoms. 5. Prevention, prophylaxis, diagnostics, treatment. 5.1. Vaccinations. 5.2. Postexposure prophylaxis. 5.3. Diagnostics. 5.4. Experimental treatment. 6. Summary